Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

LCA-PHARMA : revenue, balance sheet and financial ratios

LCA-PHARMA is a French company founded 15 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de parfumerie et de produits de beauté. Based in CLICHY (92110), this company of category PME shows in 2016 a revenue of 505 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - LCA-PHARMA (SIREN 530295757)
Indicator 2023 2016
Revenue N/C 505 220 €
Net income 227 779 € 84 814 €
EBITDA N/C 118 082 €
Net margin N/C 16.8%

Revenue and income statement

In 2023, LCA-PHARMA generates positive net income of 228 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2023: 85 k€ -> 228 k€.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

227 779 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 2%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 61%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

1.779%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

61.154%

Solvency indicators evolution
LCA-PHARMA

Sector positioning

Debt ratio
1.78 2023
2016
2023
Q1: 0.0
Med: 11.29
Q3: 62.01
Good -46 pts over 2 years

In 2023, the debt ratio of LCA-PHARMA (1.78) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
61.15% 2023
2016
2023
Q1: 7.45%
Med: 29.8%
Q3: 57.23%
Excellent +33 pts over 2 years

In 2023, the financial autonomy of LCA-PHARMA (61.1%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
1.27 years 2016
2016
Q1: 0.0 years
Med: 0.0 years
Q3: 1.66 years
Average

In 2016, the repayment capacity of LCA-PHARMA (1.27) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 261.27. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

261.27

Liquidity indicators evolution
LCA-PHARMA

Sector positioning

Liquidity ratio
261.27 2023
2016
2023
Q1: 127.81
Med: 213.37
Q3: 371.25
Good

In 2023, the liquidity ratio of LCA-PHARMA (261.27) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Interest coverage
6.24x 2016
2016
Q1: 0.0x
Med: 0.0x
Q3: 5.69x
Excellent

In 2016, the interest coverage of LCA-PHARMA (6.2x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
LCA-PHARMA

Positioning of LCA-PHARMA in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de parfumerie et de produits de beauté

Valuation estimate

Based on 64 transactions of similar company sales (all years), the value of LCA-PHARMA is estimated at 410 449 € (range 212 332€ - 2 672 003€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2023
64 tx
212k€ 410k€ 2672k€
410 449 € Range: 212 332€ - 2 672 003€
NAF 5 all-time

Valuation method used

Net Income Multiple
227 779 € × 1.8x = 410 449 €
Range: 212 332€ - 2 672 003€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 64 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de parfumerie et de produits de beauté)

Compare LCA-PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de parfumerie et de produits de beauté

Frequently asked questions about LCA-PHARMA

What is the revenue of LCA-PHARMA ?

The revenue of LCA-PHARMA in 2016 is 505 k€.

Is LCA-PHARMA profitable?

Yes, LCA-PHARMA generated a net profit of 228 k€ in 2023.

Where is the headquarters of LCA-PHARMA ?

The headquarters of LCA-PHARMA is located in CLICHY (92110), in the department Hauts-de-Seine.

Where to find the tax return of LCA-PHARMA ?

The tax return of LCA-PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does LCA-PHARMA operate?

LCA-PHARMA operates in the sector Commerce de gros (commerce interentreprises) de parfumerie et de produits de beauté (NAF code 46.45Z). See the 'Sector positioning' section above to compare the company with its competitors.